Orient Bio

Orient Bio Long-term Debt

The Long-Term Debt of Orient Bio (002630.KS) as of Oct 21, 2026 is 1.23 B KRW. In the previous year, Long-Term Debt was 1.54 B KRW — a change of -20.13% (lower).

Long-term Debt

1.23 BKRW

YoY

-20.13%

Last updated:

Long-Term Debt of Orient Bio is 2022 1.23 B KRW. Long-Term Debt of Orient Bio was 2021 1.54 B KRW. It decreases by -20.13% lower compared to the previous year.

The Orient Bio Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2014
11.73 B KRW
Jan 1, 2015
8.26 B KRW
Jan 1, 2016
10.11 B KRW
Jan 1, 2017
10.42 B KRW
Jan 1, 2018
12.23 B KRW
Jan 1, 2019
48.90 M KRW
Jan 1, 2020
1.54 B KRW
Jan 1, 2022
1.23 B KRW
The Orient Bio Long-term Debt history
YEARLong-term DebtYoY
1.23 BKRW-20.13%
1.54 BKRW+3,049.28%
48.90 MKRW-99.60%
12.23 BKRW+17.37%
10.42 BKRW+3.09%
10.11 BKRW+22.36%
8.26 BKRW-29.56%
11.73 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Long-Term Debt of Orient Bio is 1.23 B KRW in 2022.

Long-Term Debt of Orient Bio changed from 1.54 B KRW to 1.23 B KRW, representing a -20.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Orient Bio

All Key Metrics — Orient Bio